Neurogene (NASDAQ:NGNE) Now Covered by Analysts at SVB Leerink

SVB Leerink assumed coverage on shares of Neurogene (NASDAQ:NGNE) in a research report report published on Monday morning, MarketBeat reports. The firm issued an outperform rating and a $46.00 target price on the stock.

A number of other brokerages have also recently issued reports on NGNE. Stifel Nicolaus initiated coverage on Neurogene in a report on Friday, January 5th. They set a buy rating and a $31.00 target price for the company. HC Wainwright boosted their price objective on shares of Neurogene from $45.00 to $55.00 and gave the stock a buy rating in a research note on Tuesday, March 19th. William Blair initiated coverage on shares of Neurogene in a research note on Thursday, March 21st. They issued an outperform rating and a $61.00 target price on the stock. Finally, TD Cowen initiated coverage on shares of Neurogene in a research report on Thursday, January 4th. They set an outperform rating for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of Buy and a consensus price target of $48.25.

Neurogene Stock Up 11.5 %

NGNE opened at $33.40 on Monday. Neurogene has a 12 month low of $12.20 and a 12 month high of $53.00. The company has a 50-day simple moving average of $37.91. The stock has a market cap of $429.19 million, a PE ratio of -2.68 and a beta of 1.26.

Institutional Trading of Neurogene

A number of hedge funds and other institutional investors have recently made changes to their positions in NGNE. Privium Fund Management UK Ltd bought a new position in Neurogene during the 1st quarter valued at $274,000. BML Capital Management LLC bought a new position in shares of Neurogene during the fourth quarter worth about $478,000. Avidity Partners Management LP acquired a new position in Neurogene in the fourth quarter worth about $9,036,000. Finally, Great Point Partners LLC bought a new stake in Neurogene in the fourth quarter valued at about $19,268,000. Institutional investors own 52.37% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.